BioTroy Therapeutics key facts
- Developer of target discovery pharmaceutical technology designed to promote the development of new first-in-class drugs.
- It has raised $54.0M; the latest was Early Stage VC ($27.8M) in Jun 2025.
- Notable investors include Lapam Capital, Co-Win Ventures, Pudong Capital, Shanghai Healthcare Capital, Shangshi Venture Investment — 13 tracked in total.
- Status: Privately Held (backing).
Who backs BioTroy Therapeutics
13+Membership and data by Private Market View
- ·The complete investor list: 13 names
- ·Watch BioTroy Therapeutics: the Monday email on marks, rounds and moves
BioTroy Therapeutics funding rounds
No funding rounds for BioTroy Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
BioTroy Therapeutics investors
13 investors are on record for BioTroy Therapeutics, including Lapam Capital, Co-Win Ventures, Pudong Capital and Shanghai Healthcare Capital.
About BioTroy Therapeutics
Developer of target discovery pharmaceutical technology designed to promote the development of new first-in-class drugs. The company's technology focuses on tumor immunity and is used for multi-omics analysis of tumors, discovery of receptor ligands, research on target signal transduction pathways, antibody discovery and engineering, in vivo drug efficacy and large animal translational medicine, biomarkers and precision medicine, enabling patients to improve treatment effect.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Website
- biotroy.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
BioTroy Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.